42026 iPSC study
Subacute complete cervical SCI
Median motor-score change was 13 points at week 52; two participants changed from AIS A to C or D. No tumor formation or graft-related adverse events were observed over 2–4 years.
Evidence reviewed through August 2026
Spinal Cord Injury: Stem Cell Evidence, Recovery Signals and Real-World Limits
Stem cell research for spinal cord injury has reached human trials, but no cell approach can promise restored walking or a predictable outcome right now. The better question isn’t “does it work” — it’s whether your injury profile resembles the people actually studied, and what those studies did and didn’t show.[1]
Human phase 1 data availableDifferent evidence by injury stageNo guaranteed recovery rate
Information, record preparation and coordination support only. We do not diagnose, prescribe, sell cell products or promise eligibility or recovery. Medical decisions remain with licensed treating professionals.
What the human studies have actually shown
Promising signals exist. The studies are still too small to give you a personal success rate.
Read each result by exact cell product, injury timing, delivery route and study design. A result from one product does not transfer automatically to another.
102024 CELLTOP
Traumatic SCI, later after injury
Seven participants had an AIS-grade improvement from the time of injection by final follow-up. No serious adverse events were reported; headache and musculoskeletal pain were common, and MRI nerve-root changes were seen in eight participants without an apparent clinical correlation.
252022 LCTOPC1
Subacute cervical SCI
The phase 1/2a program reported neurological motor-level recovery in some participants and supported continued safety study. The trial was open-label and designed primarily around safety.
32026 NSI-566
Chronic complete cervical SCI
Participants were followed for a mean 58 months (range 54–60). No tumorigenicity or procedure-related complications were reported. Two of three showed limited clinical or electrophysiological signs of improvement, but the study had no control group and routine rehabilitation continued.
Do not convert small-study counts into your probability. Two of four is not a 50% chance for another patient. Seven of ten is not a 70% expected response. These studies differ in injury stage, product, route, baseline recovery and follow-up, and none of these counts comes from a large randomized trial.
Compare the studies, then compare the claims
The same words “stem cells” can describe very different products, doses and procedures.
These human studies should not be blended into one success rate. Their patient groups, cell products, delivery routes and recovery windows are different.
StudyInjury timingCell product and routeFollow-upWhat the data support
iPSC-NS/PC · 202614–28 days2 million iPSC-derived neural stem/progenitor cells; direct intramedullary injection2–4 yearsFirst-in-human feasibility and early safety; exploratory neurological signals.[1]
LCTOPC1 · 202221–42 days2, 10 or 20 million oligodendrocyte progenitor cells; direct spinal injection1 year primary studyDose-escalation safety and neurological follow-up; open-label phase 1/2a.[3]
CELLTOP · 20247–22 months100 million autologous adipose-derived MSCs; lumbar intrathecal infusion96 weeksPhase 1 safety and feasibility; no untreated comparison group.[2]
NSI-566 · 20261–2 yearsHuman spinal cord-derived neural stem cells; direct cervical implantation54–60 monthsLong-term phase 1 safety in three chronic AIS A participants; efficacy remains unresolved.[7]
52Historical registry patients met the 2026 iPSC study’s comparison criteria. This gives context for natural recovery, but it was not a randomized control group.
Week-52 motor scoreMedian change was +13 in the four transplanted participants versus +7 in available-case historical data and +4 with last-observation-carried-forward analysis.
AIS C or higher2 of 4 transplanted participants reached AIS C or higher. In the historical cohort, 3 of 25 available cases (12.0%) or 8 of 52 with LOCF (15.4%) reached AIS C or higher.
What this provesIt does not prove treatment efficacy. The paper itself warns that the cell group was very small and that patient-selection differences remain.
The comparison above is taken directly from the 2026 Nature Medicine report and should be read as context, not as a treatment-versus-control result.[1]
How closely does the evidence match your case?
Time since injury changes how relevant a study may be.
The 2026 iPSC study scheduled transplantation 14–28 days after injury. CELLTOP enrolled people within 12 months, with injections performed 7–22 months after injury. These are not interchangeable patient groups.[1][2]
Time since injuryRecent, subacute and long-standing injuries have different research populations.
AIS gradeComplete and incomplete injuries have different prognosis patterns and trial criteria.
Neurological levelCervical and thoracic injuries affect different functions and are often studied separately.
MRI and surgeryLesion anatomy and prior stabilization surgery help clinicians judge feasibility and risk.
Medical stabilityRespiratory status, infection, pressure injury, organ function and other complications can change suitability.
For chronic complete cervical SCI: a 2026 phase 1 NSI-566 study followed only three AIS A participants who were 1–2 years after injury. Mean follow-up was 58 months; no tumorigenicity or procedure-related complications were reported, while functional gains were limited and the study had no control group. This is human chronic-injury evidence, but it is still too small to predict an individual result.[7]
Not sure which details in your records actually matter?
Start with the injury date, neurological level, AIS grade if known, latest MRI report and surgery summary. We’ll help you organize what you have before you decide what to ask next.
What better actually means
A better neurological score is useful. It is not the same as independent walking.
Published trials use several outcomes because recovery is not one number. Before comparing claims, identify exactly which measure changed and whether that change improved everyday function.
ISNCSCI motor scoreTracks strength across defined muscle groups.
AIS gradeShows neurological classification change, not a walking guarantee.
Sensory testingTracks light touch and pinprick changes below the injury.
SCIM independenceShows whether daily activities and independence improve.
Pain and spasticityShould be separated from motor recovery so symptom change is not presented as neural restoration.
Recovery is usually measured over months, not days.The 2026 iPSC study assessed neurological outcomes through 52 weeks and continued long-term safety follow-up. Participants also received standard rehabilitation in Japan—up to 3 hours per day during the first 90 days after injury and up to 2 hours per day thereafter—so observed changes cannot be treated as a cell-only effect.[1]
<1%In recent U.S. traumatic SCI Model Systems data, fewer than 1% had complete neurological recovery by hospital discharge. This does not mean no neurological or functional improvement occurs.[5]
52 weeksThe 2026 iPSC trial’s main neurological comparison window. Long-term safety surveillance continued for 2–4 years.
96 weeksCELLTOP follow-up after a single 100-million-cell intrathecal administration.[2]
Why safety depends on the exact product and procedure
“Stem cell” is not a complete safety description.
Human studies use different cell sources, manufacturing methods, doses and delivery routes. Risk must be judged from the exact protocol, not the category name.
Product identity
Cell source, autologous or donor origin, culture method, release testing, dose and batch controls should be stated in writing.
Delivery route
The 2026 iPSC trial used direct intramedullary injection. CELLTOP used lumbar intrathecal delivery. These are different procedures.
Long-term monitoring
Imaging, neurological exams, infection surveillance and adverse-event follow-up matter because some risks may not appear immediately.
Study-specific medicines
The 2026 iPSC study used tacrolimus for six months, then tapered and stopped it by month nine. Another protocol may differ.[1]
84 AEs2026 iPSC study · four participants
No serious adverse event was attributed to the transplanted cells. Two moderate events were related to surgery. Twenty-two mild or moderate events were considered related to tacrolimus; hypomagnesemia and urinary tract infection occurred in all four participants.[1]
44 AEsCELLTOP · ten participants
Seventeen events were considered possibly related to the study drug. Eight of ten reported headache, nine of ten musculoskeletal symptoms, and eight of ten had mild cauda-equina nerve-root MRI changes without an apparent clinical correlation. No serious AEs were observed.[2]
For U.S. patients, FDA states that currently approved stem cell products are cord-blood hematopoietic progenitor cells for disorders affecting blood production, not spinal cord injury. FDA also warns that unapproved regenerative products can cause serious harm and that a ClinicalTrials.gov listing alone does not mean a product is approved for sale.[4]
Open FDA guidanceCosts without the guesswork
There is no evidence-based standard price for a stem cell intervention that restores SCI.
Current approaches remain investigational. In the 2026 iPSC study, study-specific procedures and follow-up assessments were covered by the study. Other protocols can handle costs differently.[1]
What is includedCell preparation, procedure, imaging, laboratory testing, medicines, rehabilitation, follow-up and complication management should be separated.
What may sit outsideTravel, lodging, routine care, caregiver costs and rehabilitation can fall outside a research or service quote.
What price cannot proveA higher fee, larger cell count or repeated-dose package does not establish better neurological recovery.
U.S. SCI financial context, 2024 dollars — not stem cell prices
$687,262Average first-year health-care and living expenses attributed to paraplegia in the NSCISC 2025 data sheet.
$1.41MAverage first-year expenses for high tetraplegia C1–C4 AIS ABC in the same historical U.S. dataset.[5]
Have a quote or proposal you do not fully understand?
We can help you turn it into a clear checklist: what’s being offered, what evidence matches it, what the price covers and which questions are still unanswered.
Survival, outlook and what the data can’t predict
Current stem cell studies have not established a survival benefit after SCI.
Long-term outlook is shaped by injury severity, respiratory function, age, complications, rehabilitation and ongoing care. Population data can provide context, but they cannot predict one person’s lifespan.
29%Rehospitalized in a given yearAbout 29% in the U.S. traumatic SCI dataset are rehospitalized at least once in a given year after injury.
18 daysAverage stay per rehospitalizationGenitourinary disease is the leading cause, followed by skin disease.[5]
Rehabilitation remains centralMotor practice, transfers, mobility, skin care, bladder/bowel management, pain and spasticity control remain part of long-term care.
Age 40, surviving at least 1 yearRemaining years
High tetraplegia, C1–C4 AIS ABC18.2
Low tetraplegia, C5–C8 AIS ABC22.1
Paraplegia, AIS ABC26.7
Motor functional, any level AIS D32.3
Historical U.S. population averages from the National Spinal Cord Injury Statistical Center 2025 facts sheet. They are not a personal prognosis and do not measure the effect of any cell intervention.[5]
How we help
We turn scattered records into a case that is easier to review and easier to question.
You send what you already have. We organize it, match key facts against published study populations, prepare practical questions and support appointment or medical-translation coordination when you ask. Licensed professionals make all medical decisions.
Case Evidence Snapshot
A concise summary of injury timing, level, AIS or ISNCSCI data, imaging, surgery and rehabilitation history, with the closest published study populations identified.
Evidence-Match Notes
We flag where your profile resembles a study and where it differs, so a published result is not presented as if it automatically applies to you.
Questions and Risk Checklist
Product identity, manufacturing, dose, route, regulatory status, medicines, monitoring, follow-up, rehabilitation and total cost are separated into questions you can use.
Coordination and Translation
When you choose to seek licensed evaluation in Japan, we can help coordinate communication and medical translation so records and questions are understood accurately.
Useful records to send first: injury date and cause, current neurological level, AIS grade or ISNCSCI exam if known, latest MRI report, surgery summary, ventilation history, major complications, current medicines and recent rehabilitation progress.
Research is still moving forward
New trials matter because the unanswered questions are still being tested.
A registry record confirms that a study plan exists. It does not prove benefit, guarantee recruitment or make a product standard care. Check the current record directly.
DOSED / LCTOPC1 delivery-device study
The registry plans 3–5 subacute participants 21–42 days after injury and 3–5 chronic participants 1–5 years after injury, with one 10-million-cell injection. Status was listed as Recruiting with the record last updated February 12, 2026.[6]
Open registry recordCELLTOP phase 1 record
The completed record provides protocol context for the 10-participant autologous adipose-derived MSC study and its published 96-week follow-up.
Open registry recordLong-term safety needs long-term observation
Five people with acute complete thoracic SCI received 2 million LCTOPC1 cells 7–14 days after injury. Across 49 of 50 planned annual visits through 10 years, no unanticipated serious adverse event related to LCTOPC1 was reported and no enlarging mass, neurological decline, further cord damage or syrinx formation was seen.[8]
Review 10-year safety publication
Keep reading on related topics
Read the evidence around the product, the research field and related symptoms.
Spinal Cord Injury and Regenerative Medicine in JapanIndependent evidence, study-record and regulatory context.Regenerative Medicine OverviewBrowse the wider cell-based care and research topics on the site.Cell Processing and Quality OverviewSee why product identity, handling and manufacturing details matter.Chronic Pain OverviewRelated information for people managing persistent pain alongside long-term recovery.
Questions worth a clear answer before you commit
Use specific answers, not broad promises.
A serious discussion should identify the exact product, evidence, procedure, follow-up and cost. If those details are missing, the proposal is not ready to compare.
Can current data tell me my chance of walking again?
No. Small early-phase studies can show safety, feasibility and neurological changes, but they cannot give a reliable personal probability of independent walking. AIS conversion or motor-score improvement should not be translated into a walking percentage.
Does chronic SCI have the same evidence as recent injury?
No. The 2026 iPSC study involved subacute complete cervical injury with transplantation 14–28 days after injury. Later-stage studies use different products, routes and populations. Chronic complete injury therefore needs separate evidence.
Does a higher cell dose mean a better result?
Not by itself. Dose must be studied for a specific cell product and route. Different trials use very different doses, and there is no general rule that more cells produce better neurological recovery.
What records should I prepare first?
Start with injury date and cause, neurological level, AIS or ISNCSCI results if available, latest MRI report, surgery notes, major complications, medicines, ventilation history and recent rehabilitation progress.
If my injury is more than five years old, do these studies answer my case?
Not directly. The chronic 2026 NSI-566 study involved injuries 1–2 years old, and the current DOSED registry includes a chronic window of 1–5 years. A longer-standing injury therefore falls outside those specific study windows and needs separate evidence rather than extrapolation from them.
What should I ask before paying?
Ask for the exact product identity, cell source, manufacturing controls, dose, route, regulatory status, procedure risks, medicines, follow-up schedule, rehabilitation plan, total cost and what happens if a complication occurs.
Why should I know my AIS grade or ISNCSCI result?
These are standardized neurological classifications used to describe injury level and completeness and are central to trial eligibility and outcome tracking. If your report contains an AIS grade, neurological level or ISNCSCI motor/sensory scores, include them in your records.[9]
Start with what you already know
A clearer next step begins with a reviewable set of facts.
Send the injury date, current neurological level and AIS grade if known, latest MRI report, surgery summary and recent rehabilitation status. We’ll organize it, match it against published evidence and prepare the questions that matter before you commit.